Median overall survival was significantly longer in the vemurafenib group than in the dacarbazine group ( @ months -LSB- @ % CI @-@ -RSB- vs @ months -LSB- @-@ -RSB- ; hazard ratio -LSB- HR -RSB- @ -LSB- @ % CI @-@ -RSB- ; p = @ ) , as was median progression-free survival ( @ months -LSB- @ % CI @-@ -RSB- vs @ months -LSB- @-@ -RSB- ; HR @ -LSB- @ % CI @-@ -RSB- ; p < @ ) .